




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 233/86, A61K 31/415		A1	(11) International Publication Number: WO 97/19931
			(43) International Publication Date: 5 June 1997 (05.06.97)
(21) International Application Number: PCT/US96/19108 (22) International Filing Date: 25 November 1996 (25.11.96) (30) Priority Data: 60/007,653 28 November 1995 (28.11.95) US 08/563,841 28 November 1995 (28.11.95) US		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralta Farms, Madison, NJ 07940-0874 (US). (72) Inventors: ELOKDAH, Hassan, Mahmoud; 1487 Merrick Road, Yardley, PA 19067 (US). SULKOWSKI, Theodore, Sylvester; 316 Rockland Road, Wayne, PA 19087 (US). STRIKE, Donald, Peter; 445 Iven Avenue, St. Davids, PA 19087 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: 2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES

(57) Abstract

The compounds of formula (I): wherein R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, hydroxy, alkanoyloxy, aroyloxy or arylalkanoyloxy; R³ is alkyl, aryl or arylalkyl; or a pharmaceutically acceptable salt thereof, are use for increasing HDL blood levels.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES

Background of the Invention

5

Numerous studies have demonstrated that both the risk of coronary heart disease (CHD) in humans and the severity of experimental atherosclerosis in animals are inversely correlated with serum HDL cholesterol (HDL-C) concentrations (Russ et al, Am. J. Med., 11 (1951) 480-493; Gofman et al, Circulation, 34 (1966) 679-697; 10 Miller and Miller, Lancet, 1 (1975) 16-19; Gordon et al, Circulation, 79 (1989) 8-15; Stampfer et al, N. Engl. J. Med., 325 (1991) 373-381; Badimon et al, Lab. Invest., 60 (1989) 455-461). Atherosclerosis is the process of accumulation of cholesterol within the arterial wall which results in the occlusion, or stenosis, of coronary and cerebral arterial vessels and subsequent myocardial infarction and stroke. Angiographical 15 studies have shown that elevated level of some HDL particles in humans appears to be correlated to a decreased number of sites of stenosis in the coronary arteries of humans (Miller et al, Br. Med. J., 282 (1981) 1741-1744).


There are several mechanisms by which HDL may protect against the 20 progression of atherosclerosis. Studies in vitro have shown that HDL is capable of removing cholesterol from cells (Picardo et al, Arteriosclerosis, 6 (1986) 434-441). Data of this nature suggest that one antiatherogenic property of HDL may lie in its 25 ability to deplete tissues of excess free cholesterol and eventually lead to the delivery of this cholesterol to the liver (Glomset, J. Lipid Res., 9 (1968) 155-167). This has been supported by experiments showing efficient transfer of cholesterol from HDL to the liver (Glass et al, Circulation, 66 (Suppl. I) (1982) 102; MacKinnon et al, J. Biol. Chem., 261 (1986) 2548-2552). In addition, HDL may serve as a reservoir in the circulation for apoproteins necessary for the rapid metabolism of triglyceride-rich 30 lipoproteins (Grow and Fried, J. Biol. Chem., 253 (1978) 1834-1841; Lagocki and Scanu, J. Biol. Chem., 255 (1980) 3701-3706; Schaefer et al, J. Lipid Res., 23 (1982) 1259-1273). Accordingly, agents which increase HDL cholesterol concentrations are useful as anti-atherosclerotic agents, particularly in the treatment of dyslipoproteinemias and coronary heart disease.

35

US 5,411,981 discloses N-phenyl imidazolidines of the following formula

-2-


(A-I) as anti-androgenic agents useful in the treatment of cancers of the breast, brain, ovaries, bladder, liver and kidney:



(A-I)

5

in which -A-B- is



(a)


(b)

10 where R¹ is cyano, nitro or halogen; R² is trifluoromethyl or halogen; X is oxygen or sulfur; Y is oxygen, sulfur or nitrogen and R³ is hydrogen or a vast variety of organic groups.


15 Related publication EP 578516 emphasizes compounds of formula (A-Ia), with special emphasis on the 4-cyano-2-trifluoromethyl-phenyl group in each of the disclosed species.

WO 94/20460 discloses a genus of compounds of formula (A-II) as angiotensin-II receptor antagonists, useful for the treatment of hypertension, congestive heart failure, renal failure and glaucoma.

20



where HET is



(A-II)


(A-III)

-3-

In the generic disclosure, HET represents numerous heterocycles, one of which is an imidazolidinone (A-III) in which R² may be an 2-8 C alkylthio group among other things. There is no specific example of a compound disclosed in the document that corresponds with those variables. R²² is a 3-4 membered polymethylene (spiro) group.

Description of Invention

10 In accordance with this invention there is provided a group of 2-(substituted sulfanyl) dihydro-imidazolones of formula I,



wherein

15 R is phenyl or phenyl optionally substituted with one or more groups the same or different selected from halogen, alkyl of 1 to 6 carbon atoms, perfluoroalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms, hydroxy, alkanoyloxy of 2 to 6 carbon atoms, aroyloxy of 7 to 11 carbon atoms or arylalkanoyloxy of 8 to 16 carbon atoms;

20 R³ is alkyl of 1 to 6 carbon atoms, aryl of 6 to 10 carbon atoms or arylalkyl of 7 to 12 carbon atoms;

or a pharmaceutically acceptable salt thereof.


25 The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. The terms alkyl and alkoxy as used as a group or part of a group, e.g perfluoro-alkyl or -alkoxy means a straight chain or branched chain, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, neopentyl, 30 hexyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, hexyloxy, and the like.

-4-

Examples of halogen are fluorine, chlorine, bromine and iodine. Examples of aryl as a group or part of a group such as arylalkyl or aroyl are phenyl and naphthyl. Examples of alkanoyloxy as a group or part of a group are acetoxy, propanoyloxy or butanoyloxy.

5

A preferred group of compounds are those of formula I:



10 wherein

R is phenyl or phenyl optionally substituted with one or more groups the same or different selected from halogen, alkyl of 1 to 3 carbon atoms, perfluoromethyl, alkoxy of 1 to 3 carbon atoms, perfluoromethoxy, hydroxy or alkanoyloxy of 2 to 4 carbon atoms;

15 R³ is alkyl of 1 to 3 carbon atoms or arylalkyl or 7 to 9 carbon atoms; or a pharmaceutically acceptable salt thereof.

The most preferred compounds of this invention are:

20 2-Ethylsulfanyl-3-(4-fluorophenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

3-(5-Chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

25 3-(5-Chloro-2-methoxyphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

30 3-(2,6-Dichlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

-5-

2-Benzylsulfanyl-3-(5-chloro-2-methylphenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

5 3-(2-Chlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

10 2-Ethylsulfanyl-3-(2-tolyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;


15 3-(2-Chloro-6-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

20 2-Ethylsulfanyl-3-phenyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

15 3-(2,6-Dimethylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof;

This invention also provides processes for preparing the compounds of formula 20 I or pharmaceutically acceptable salts thereof which processes comprise:

a) reacting a 2-thioxo-imidazolidin-4-one of formula (A):




25

wherein R is as defined above with methyl iodide to give a corresponding compound of formula I wherein R³ is methyl, or

b) reacting a thiourea amide of formula 3:

-6-



wherein R is as defined above, with a compound of formula:

5 $\mathbb{R}^3 - X$


where R^3 is as defined above and X is a halogen to give a compound of formula I wherein R and R^5 are as defined above,

and if desired isolating the compound of formula I as the free base or converting to a pharmaceutical salt thereof.

10

With regard to process a) the compounds of this invention where R^3 is methyl (B) can be prepared by alkylation of 2-thioxo-imidazolidin-4-ones (A) with methyl iodide. The reaction proceeds in poor yield. The product is difficult to purify as a pharmaceutically acceptable salt. The alkylation has not been successfully carried out with alkyl iodides larger than methyl.


15



With regard to process b) the compounds of the present invention are prepared according to the preferred general sequence of reactions outlined in the scheme below:

20

-7-



In a preferred sequence an amino acid amide hydrochloride (1) is converted to the base (2) with sodium methoxide in methanol. An appropriate isothiocyanate is 5 added at room temperature to the amino acid amide in chloroform or methylene chloride. The mixture is heated to reflux, then heating is discontinued and stirring is continued for 20 minutes to 3 hours. The thiourea-amide (3) is isolated by standard procedures. In an alternative procedure, (3) can be obtained from the amino acid amide hydrochloride (1). In this procedure, (1) is reacted with an isothiocyanate in the 10 presence of a base such as triethylamine. The thiourea-amide (3) is reacted with two equivalents of alkyl halide (or aryl halide) in ethanol at reflux for 2 to 5 hours. The ammonia that forms during cyclization effectively scavenges the hydrohalide formed during alkylation, allowing the title compounds (4) to be isolated as the free base. Desired salts can be prepared by standard methods.

15

This invention also provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutical salt thereof either alone or in combination with excipients (i.e. pharmaceutically acceptable carrier or materials with no pharmacological effects). Such compositions are useful in the treatment of 20 atherosclerotic conditions such as dyslipoproteinemias and coronary heart disease, in that they increase the blood serum high density lipoprotein concentration of mammals treated with the compounds.

The precise dosage to be employed depends upon several factors including the 25 host, whether in veterinary medicine or human medicine, the nature and severity of the

condition being treated, the mode of administration and the particular active substance employed. The compounds may be administered by any conventional route, in particular enterally, preferably orally in the form of tablets or capsules. Administered compounds can be in the free form or pharmaceutically acceptable salt form as 5 appropriate, for use as a pharmaceutical, particularly for use in the prophylactic or curative treatment of atherosclerosis and sequelae (angina pectoris, myocardial infarction, arrhythmias, heart failure, kidney failure stroke, peripheral arterial occlusion, and related disease states). These measures will slow the rate of progress of the disease state and assist the body in reversing the process direction in a natural 10 manner.

Any suitable carrier known to the art can be used to prepare the pharmaceutical compositions. In such a composition, the carrier may be a solid, liquid or mixture of a solid and a liquid. Solid compositions include powders, tablets and capsules. A solid 15 carrier can be one or more substances which may also act as a flavoring agent, lubricant, solubilizer, suspending agent, binder, or tablet disintegrant. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. 20 Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, hydroxymethyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. Encapsulating materials may also be employed with the compounds of this invention, and the term "composition" is intended to include the active ingredient in 25 combination with an encapsulating material as a formulation, with or without other carriers. Cachets may also be used in the delivery of the anti-atherosclerotic medicament of this invention.

Sterile liquid compositions include solutions, suspensions, emulsions, syrups 30 and elixirs. The compounds of this invention may be dissolved or suspended in the pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. Preferably the liquid carrier is one suitable for parenteral injection. Where the compounds are sufficiently soluble they can be dissolved directly in normal saline with or without the use of suitable organic solvents, such as propylene glycol or 35 polyethylene glycol. If desired, dispersions of the finely divided compounds can be

made-up in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, such as arachis oil. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by intramuscular, intraperitoneal or subcutaneous injection. In many instances a liquid composition form may be used instead of the 5 preferred solid oral method of administration.

It is preferred to prepare unit dosage forms of the compounds for standard administration regimens. In this way, the composition can be subdivided readily into smaller doses at the physicians direction. For example, unit dosages may be made up 10 in packeted powders, vials or ampoules and preferably in capsule or tablet form. The active compound present in these unit dosage forms of the composition may be present in an amount of from about one gram to about fifteen grams or more, for single or multiple daily administration, according to the particular need of the patient. The daily dose of active compound will vary depending upon the route of administration, the 15 size, age and sex of the patient, the severity of the disease state, and the response to the therapy as traced by blood analysis and the patients recovery rate. By initiating the treatment regimen with a minimal daily dose of about one gram, the blood levels of HDL and the patients symptomatic relief analysis may be used to determine whether a larger dose is indicated. Based upon the data presented below, the projected daily dose 20 for both human and veterinary use will be from about 10 to about 200 milligrams/kilogram per day. However, in general, satisfactory results are indicated to be obtained at daily dosages in the range of from 400 milligrams to about 2000 milligrams, conveniently administered in divided doses two to four times a day.

25 The ability of the compounds of this invention to increase blood serum HDL levels was established by the following standard experimental procedure for determination of HDL cholesterol:

Male Sprague-Dawley rats weighing 200-225 g are housed two per cage and 30 fed Purina Rodent Chow Special Mix 5001-S supplemented with 0.25 % cholic acid and 1.0 % cholesterol and water ad libitum for 8 days. Each test substance is administered to a group of six rats fed the same diet with the test diet mixed in as 0.005 - 0.1 % of the total diet. Body weight and food consumption are recorded prior to diet administration and at termination. Typical doses of the test substances are 5 - 100 35 mg/kg/day.

-10-

At termination, blood is collected from anesthetized rats and the serum is separated by centrifugation. Total serum cholesterol is assayed using the Sigma Diagnostics enzymatic kit for the determination of cholesterol, Sigma Procedure No. 5 352, modified for use with ninety-six well microtiter plates. After reconstitution with water the reagent contains 300 U/l cholesterol oxidase, 100 U/l cholesterol esterase, 1000 U/l horse radish peroxidase, 0.3 mmoles/l 4-aminoantipyrine and 30.0 mmoles/l 10 p-hydroxybenzenesulfonate in a pH 6.5 buffer. In the reaction cholesterol is oxidized to produce hydrogen peroxide which is used to form a quinoneimine dye. The concentration of dye formed is measured spectrophotometrically by absorbance at 490 nm after incubation at 25 °C for 30 minutes. The concentration of cholesterol was determined for each serum sample relative to a commercial standard from Sigma.

HDL cholesterol concentrations in serum are determined by separation of 15 lipoprotein classes by fast protein liquid chromatography (FPLC) by a modification of the method of Kieft et al., J. Lipid Res., 32 (1991) 859-866. 25 ul of serum is injected onto Superose 12 and Superose 6 (Pharmacia), in series, with a column buffer of 0.05 M Tris (2-amino-2-hydroxymethyl-1,3-propanediol) and 0.15 M sodium chloride at a 20 flow rate of 0.5 ml/min. The eluted sample is mixed on line with Boehringer-Mannheim cholesterol reagent pumped at 0.2 ml/min. The combined eluents are mixed and incubated on line through a knitted coil (Applied Biosciences) maintained at a temperature of 45C. The eluent is monitored by measuring absorbance at 490 nm and gives a continuous absorbance signal proportional to the cholesterol concentration. The relative concentration of each lipoprotein class is calculated as the per cent of total 25 absorbance. HDL cholesterol concentration, in serum, is calculated as the per cent of total cholesterol as determined by FPLC multiplied by the total serum cholesterol concentration.

The compounds of the present invention increase HDL cholesterol 30 concentrations as summarized in Table I:

-11-

Table I

Compound of Example	Dose (mg/kg/day)	Duration of Treatment (days)	HDL Cholesterol Level Increase (%)
1	80	8	140
2	100	8	153
3	100	8	66
4	70	8	128
5	100	8	102
6	100	8	74
7	100	8	139
8	100	8	71
9	100	8	89
10	100	8	32
11	100	8	26
12	100	8	45
13	100	8	39
14	100	8	75

EXAMPLE 1

5

2-Ethylsulfonyl-3-(4-fluorophenyl)-3,5-dihydro-imidazol-4-one

Glycinamide (5.0 g) and 4-fluorophenyl-isothiocyanate (9.18 g) were stirred in chloroform (200 mL). The mixture was heated at reflux for 5 minutes then stirred at ambient temperature for 20 minutes. The precipitated solid was collected by filtration, washed with chloroform and air dried to give 2-[3-(4-fluorophenyl)-thioureido]-acetamide (10.7 g) as a light pink solid, m.p. 168-170° C (dec.). Mass spectrum (EI, M⁺) *m/z* 277. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.97 (broad s, 1H), 7.82 (broad s, 1H), 7.45-7.52 (m, 3H), 7.10-7.17 (m, 3H), and 4.06 ppm (s, 2H).

10
15

-12-

A mixture of 2-[3-(4-fluorophenyl)-thioureido]-acetamide (9.1 g) and ethyl iodide (12.5 g) was heated at reflux in ethanol (200 mL) for 4 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (500 mL) then washed with water. The organic phase was extracted with 2N HCl (2 X 400 mL). The acid extract 5 was made basic with 5% sodium bicarbonate solution. The precipitate was collected by filtration and dried. Crystallization from diethyl ether afforded the title compound (2.85 g) as an off-white solid, m.p. 114-115° C. Anal. Calcd. for. C₁₁ H₁₁ F N₂ O S: C, 55.45; H, 4.65; N, 11.76. Found: C, 55.17; H, 4.54; N, 11.81. Mass spectrum (EI, M.⁺) *m/z* 238. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.32-7.39 (m, 4H), 4.30 (s, 2H), 10 3.07 (q, 2H), and 1.28 ppm (t, 3H).

EXAMPLE 2

3-(5-Chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-15 imidazol-4-one

Glycinamide (10.08 g) and 5-chloro-2-methylphenyl-isothiocyanate (23 g) were heated at reflux in chloroform (300 mL) for 30 minutes. The mixture was then stirred at ambient temperature for 3 hours. The precipitated solid was collected by filtration, 20 washed with chloroform and air dried to give 2-[3-(5-chloro-2-methylphenyl)-thioureido]-acetamide (28.5 g), m.p. 162-164° C. Mass spectrum (EI, M.⁺) *m/z* 257/259. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.46 (s, 1H), 7.83 (s, 1H), 7.51 (d, 2H), 7.24 (d, 1H), 7.24 (d, 1H), 7.18 (d, 1H), 7.15 (m, 2H), 4.06 (d, 2H), and 2.16 ppm (s, 3H).

25 A mixture of 2-[3-(5-chloro-2-methylphenyl)-thioureido]-acetamide (25.8g) and ethyl iodide (32.0 g) was heated at reflux in ethanol (500 mL) for 5 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (500 mL) and water (300 mL). The organic phase was washed with water, dried over anhydrous MgSO₄, then 30 evaporated to dryness. The residue was triturated with diethyl ether and the solid was collected by filtration and dried to give the title compound (17.0 g) as a yellow solid, m.p. 137-139° C. Anal. Calcd. for. C₁₂ H₁₃ Cl N₂ O S: C, 53.63; H, 4.88; N, 10.42. Found: C, 53.58; H, 4.74; N, 10.32. Mass spectrum (EI, M.⁺) *m/z* 268/270. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.45-7.49 (m, 1H), 7.40-7.43 (m, 2H), 4.35 (dd, 35 2H), 3.07 (m, 2H), 2.1 (s, 3H), and 1.28 ppm (t, 3H).

EXAMPLE 33-(5-Chloro-2-methoxyphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

5

A mixture of glyciamide hydrochloride (5.5 g), triethyl amine (5.05 g), 5-chloro-2-methoxyphenyl-isothiocyanate (9.95 g), and chloroform (500 mL) were heated at reflux for 3 hours. The mixture was then cooled to ambient temperature and 10 washed with water (300 mL). The organic phase was separated. Precipitate formed upon standing. The solid was collected by filtration, washed with water, then with diethyl ether and air dried to give 2-[3-(5-chloro-2-methoxyphenyl)-thioureido]-acetamide (12.8 g), m.p. 166-169° C (dec.). This compound was used without further purification for the preparation of the title compound.

15

A mixture of 2-[3-(5-chloro-2-methoxyphenyl)-thioureido]-acetamide (11.0 g) and ethyl iodide (12.5 g) in ethanol (400 mL) was heated at reflux for 4.5 hours. The solvent was evaporated. The residue was dissolved in chloroform (500 mL) and washed with water. The organic phase was dried over anhydrous MgSO_4 , then 20 evaporated to dryness. The residue was crystallized from ethanol to give the title compound (6.1 g) as a tan solid, m.p. 113-115° C. Anal. Calcd. for. $\text{C}_{12}\text{H}_{13}\text{ClN}_2\text{O}_2\text{S}$: C, 50.61; H, 4.60; N, 9.84. Found: C, 50.32; H, 4.59; N, 9.77. Mass spectrum (ESI $^+$, $[\text{M}+\text{H}]^+$) m/z 285/287. $^1\text{H-NMR}$ (DMSO-d₆; 400 MHz) δ 7.53 (m, 1H), 7.41 (d, 1H), 7.22 (d, 1H), 4.31 (dd, 2H), 3.77 (s, 3H), 3.05 (m, 2H), and 1.26 ppm 25 (t, 3H).

EXAMPLE 43-(2,6-Dichlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

30

2-[3-(2,6-Dichlorophenyl)-thioureido]-acetamide was prepared by the procedure described in Example 2 using 40.8 g of 2,6-dichlorophenyl-isothiocyanate and 29.6 g of glyciamide. The product was obtained (54 g) as a solid, m.p. 189-191° C. Mass spectrum (+FAB, $[\text{M}+\text{H}]^+$) m/z 278/280/282. This intermediate was used in 35 the next paragraph without further purification.

-14-

The title compound was prepared by the procedure described in Example 2 using 27.8 g of 2-[3-(2,6-dichlorophenyl)-thioureido]-acetamide and 31.2 g of ethyl iodide. 12.8 g of the title compound was obtained, m.p. 122-124° C. Anal. Calcd. for. 5 C₁₁ H₁₀ Cl₂ N₂ O S: C, 45.69; H, 3.49; N, 9.69. Found: C, 45.62; H, 3.33; N, 9.43. Mass spectrum (+FAB, [M+H]⁺) *m/z* 289/291/293. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.72 (s, 1H), 7.70 (s, 1H), 7.58 (t, 1H), 4.50 (s, 2H), 3.10 (q, 2H), and 1.27 ppm (t, 3H).

10

EXAMPLE 5

2-Benzylsulfonyl-3-(5-chloro-2-methylphenyl)-3,5-dihydro-imidazol-4-one

15 A mixture of 2-[3-(5-chloro-2-methylphenyl)-thioureido]-acetamide (20.6g), benzyl chloride (25.0 g), and ethanol (350 mL) was heated at reflux for 2.5 hours. The insolubles were removed by filtration and discarded. The filtrate was concentrated to one-half volume. Diethyl ether (300 mL) was added. The precipitated solid was separated by filtration and discarded. The filtrate was evaporated to dryness. The 20 residue was dissolved in chloroform (300 mL) and washed with water. The organic phase was dried over anhydrous MgSO₄, decolorized on carbon then evaporated to dryness. The residue was triturated with diethyl ether to give the title compound (14.2 g) as an off-white solid, m.p. 140-142° C. Anal. Calcd. for. C₁₇ H₁₅ Cl N₂ O S: C, 61.72; H, 4.57; N, 8.47. Found: C, 61.62; H, 4.39; N, 8.37. Mass spectrum (EI, M⁺) *m/z* 330/332. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.46 (m, 1H), 7.42 (m, 2H), 25 7.38 (d, 2H), 7.22-7.32 (m, 3H), 4.31-4.48 (m, 4H), and 2.06 ppm (s, 3H).

EXAMPLE 6

3-(2-Chlorophenyl)-2-ethylsulfonyl-3,5-dihydro-imidazol-4-one

30 2-[3-(2-Chlorophenyl)-thioureido]-acetamide was prepared by the procedure described in Example 3 using 16.95 g of 2-chlorophenyl-isothiocyanate and equivalent amounts of all other reactants. 18.8 Grams of the desired product was obtained, m.p. 161-163° C. Anal. Calcd. for. C₉ H₁₀ Cl N₃ O S: C, 44.35; H, 4.414; N, 17.24.

-15-

Found: C, 43.99; H, 3.91; N, 17.12. Mass spectrum (+FAB, $[M+H]^+$) m/z 244/246. 1H -NMR (DMSO-d₆; 400 MHz) δ 9.57 (s, 1H), 8.06 (t, 1H), 7.71 (d, 1H), 7.52 (s, 1H), 7.47 (m, 1H), 7.28-7.32 (m, 1H), 7.18-7.22 (m, 2H), and 4.09 ppm (d, 2H).

5 A mixture of 2-[3-(2-chlorophenyl)-thioureido]-acetamide (12.2 g), ethyl iodide (15.6 g), and ethanol (200 mL) was heated at reflux for 5 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (400 mL) and water (300 mL). The organic phase was washed with water (2x300 mL). The organic phase was then extracted with 2N HCl (2x500 mL). The acid extract was neutralized with solid sodium 10 bicarbonate and extracted with ethyl acetate. The organic phase was washed with water, dried over anhydrous MgSO₄ then evaporated to dryness. The residue was dissolved in ethanol and the solution was saturated with hydrogen chloride. The solvent was evaporated and the residue was crystallized from ethyl acetate to give the hydrochloride salt of the title compound (8.4 g) as an off-white solid, m.p. 149-150° C (dec.). Anal. 15 Calcd. for. C₁₁ H₁₁ Cl N₂ O S . HCl: C, 45.37; H, 4.15; N, 9.62. Found: C, 44.97; H, 4.06; N, 9.51. Mass spectrum (EI, M⁺) m/z 254/256. 1H -NMR (DMSO-d₆; 400 MHz) δ 7.69 (m, 1H), 7.50-7.58 (m, 3H), 4.45 (q, 2H), 3.11-3.17 (m, 2H), and 1.27 ppm (t, 3H).

20

EXAMPLE 7

2-Ethylsulfanyl-3-(2-tolyl)-3,5-dihydro-imidazol-4-one

2-[3-(2-Tolyl)-thioureido]-acetamide was prepared by the procedure described 25 in the first paragraph of Example 3 using 14.9 g of 2-tolyl-isothiocyanate and equivalent amounts of all other reactants. 17.1 Grams of product was obtained, m.p. 169-171° C (dec.). This compound was used without further purification in the next paragraph.

30 The title compound was prepared by the procedure described in Example 6 using 11.2 g of 2-[3-(2-tolyl)-thioureido]-acetamide and 15.6 g of ethyl iodide. Crystallization from ethyl acetate afforded the hydrochloride salt of the title compound as a white solid (6.8 g), m.p. 156-158° C (dec.). Anal. Calcd. for. C₁₂ H₁₄ N₂ O S . HCl: C, 53.23; H, 5.58; N, 10.34. Found: C, 52.96; H, 5.49; N, 10.25. Mass

-16-

spectrum (EI, M.⁺) *m/z* 234. ¹H-NMR (DMSO-d₆; 400 MHz) δ 8.75 (broad s, 2H), 7.43 (m, 2H), 7.35 (m, 1H), 7.30 (m, 1H), 4.53 (q, 2H), 3.18-3.20 (m, 2H), and 1.29 ppm (t, 3H).

5

EXAMPLE 8

3-(2-Chloro-6-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

10 2-[3-(2-Chloro-6-methylphenyl)-thioureido]-acetamide was prepared by the procedure described in Example 2 using 18.3 g of 2-chloro-6-methylphenyl-isothiocyanate and 12.0 g of glyciamide. 22.8 Grams of the product was obtained, m.p. 161-163° C (dec.). This compound was used without further purification in the next paragraph.

15

The title compound was prepared by the procedure described in Example 6 using 12.9 g of 2-[3-(2-chloro-6-methylphenyl)-thioureido]-acetamide, and 18.0 g of ethyl iodide. The hydrochloride salt was prepared in ethereal hydrogen chloride. Crystallization from ethyl acetate afforded the title compound as the mono-
20 hydrochloride as a light yellow solid (4.9 g), m.p. 152-154° C (dec.). Anal. Calcd. for. C₁₂ H₁₃ Cl N₂ O S . HCl: C, 47.22; H, 4.62; N, 9.18. Found: C, 46.99; H, 4.60; N, 9.16. Mass spectrum (+FAB, [M+H]⁺) *m/z* 269/271. ¹H-NMR (DMSO-d₆; 400 MHz) δ 8.28 (broad s, 2H), 7.51 (m, 1H), 7.44 (t, 1H), 7.39 (m, 1H), 4.51 (q, 2H), 3.12 (q, 2H), 2.17 (s, 3H), and 1.27 ppm (t, 3H).

25

EXAMPLE 9

2-Ethylsulfanyl-3-phenyl-3,5-dihydro-imidazol-4-one

30 A mixture of glyciamide hydrochloride (8.25 g), triethyl amine (10.0 g), phenyl-isothiocyanate (10.1 g), and methylene chloride (300 mL) was heated at reflux for 1 hour. The mixture was stirred at ambient temperature for 2 hours. The precipitate was collected by filtration, washed with methylene chloride, then with diethyl ether and air dried to give 2-(3-phenyl-thioureido)-acetamide (9.7 g), m.p. 150-152° C. Anal.

-17-

Calcd. for. C₉ H₁₁ N₃ O S: C, 51.66; H, 5.30; N, 20.08. Found: C, 51.41; H, 5.04; N, 20.02. Mass spectrum (EI, M⁺) *m/z* 209. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.88 (s, 1H), 7.70 (t, 1H), 7.52 (s, 1H), 7.47 (d, 2H), 7.31 (t, 2H), 7.15 (s, 1H), 7.09 (t, 1H), and 4.08 ppm (d, 2H).

5

A mixture of 2-(3-phenyl-thioureido)-acetamide (7.1 g), ethyl iodide (18.0 g), and ethanol (300 mL) was heated at reflux for 2 hours. The solvent was evaporated. The residue was dissolved in chloroform (300 mL) and water (300 mL). The organic phase was washed with water, dried over anhydrous MgSO₄, then evaporated to dryness. The residue was crystallized from ethyl acetate/hexane to give the title compound (3.1 g), m.p. 79-81° C. Anal. Calcd. for. C₁₁ H₁₂ N₂ O S: C, 59.97; H, 5.49; N, 12.72. Found: C, 59.67; H, 5.35; N, 12.70. Mass spectrum (EI, M⁺) *m/z* 220. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.43-7.52 (m, 3H), 7.28-7.31 (m, 2H), 4.32 (s, 2H), 3.07 (q, 2H), and 1.27 ppm (t, 3H).

15

EXAMPLE 10

2-Ethylsulfanyl-3-(5-fluoro-2-methylphenyl)-3,5-dihydro-imidazol-4-one

20

A mixture of glyciamide hydrochloride (4.42 g), 5-fluoro-2-methylphenyl-isothiocyanate (6.68 g), triethyl amine (4.1 g), and chloroform (150 mL) was stirred at ambient temperature for 18 hours. The precipitate was collected by filtration, washed with chloroform and air dried to give 2-[3-(5-Fluoro-2-methylphenyl)-thioureido]-acetamide (7.6 g), m.p. 172-174° C (dec.). This compound was used without further purification in the next paragraph.

30

A mixture of 2-[3-(5-fluoro-2-methylphenyl)-thioureido]-acetamide (6.0 g), ethyl iodide (15.6 g), and ethanol (120 mL) was heated at reflux for 4 hours. The solvent was evaporated. The residue was treated with ethyl acetate (400 mL) and filtered. The filtrate was washed with water (300 mL). The organic phase was evaporated to dryness. The residue was dissolved in ethanol. The solution was saturated with hydrogen chloride. The solvent was evaporated and the residue was crystallized from ethyl acetate and dried under vacuum to give the mono-hydrochloride

-18-

of the title compound as a white solid (4.2 g), m.p. 181-183° C. Anal. Calcd. for. C₁₂H₁₃FN₂OS . HCl: C, 49.91; H, 4.89; N, 9.70. Found: C, 49.83; H, 4.82; N, 9.71. Mass spectrum (+FAB, [M+H]⁺) *m/z* 253. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.50-8.45 (broad s, 2H), 7.45 (m, 1H), 7.27-7.34 (m, 2H), 4.48 (q, 2H), 3.21 (m, 2H), 2.10 (s, 3H), and 1.29 ppm (t, 3H).

EXAMPLE 11

3-(3-Chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-10 imidazol-4-one

A mixture of glycinamide hydrochloride (6.1 g), 3-chloro-2-methylphenyl-isothiocyanate (10.1 g), triethyl amine (5.6 g), and chloroform (200 mL) was heated at reflux for 3 hours then cooled to ambient temperature. The precipitate was collected by 15 filtration, washed with chloroform and air dried to give 2-[3-(3-chloro-2-methylphenyl)-thioureido]-acetamide (12.5 g), m.p. 162-164° C (dec.). This compound was used without further purification for the preparation of the title compound of step 2.

20 The title compound was prepared by the procedure described in Example 6 using 12.0 g of 2-[3-(3-chloro-2-methylphenyl)-thioureido]-acetamide, and 25.0 g of ethyl iodide. The hydrochloride salt was prepared in ethereal hydrogen chloride. Crystallization from ethyl acetate afforded the title compound as a white solid, mono-hydrochloride (5.1 g), m.p. 161-163° C (dec.). Anal. Calcd. for. C₁₂H₁₃ClN₂OS . HCl: C, 47.22; H, 4.62; N, 9.18. Found: C, 47.03; H, 4.40; N, 9.09. Mass spectrum (+FAB, [M+H]⁺) *m/z* 269/271. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.05-25 9.85 (broad s, 2H), 7.62 (d, 1H), 7.39 (t, 1H), 7.33 (d, 1H), 4.48 (q, 2H), 3.20 (m, 2H), 2.15 (s, 3H), and 1.29 ppm (t, 3H).

-19-

EXAMPLE 12

3-(3-Chloro-4-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

5

2-[3-(3-Chloro-4-methylphenyl)-thioureido]-acetamide was prepared by the procedure described Example 11 using 18.36 g of 3-chloro-4-methylphenyl-isothiocyanate, 11.05 g of glyciamide hydrochloride, 10.1 g of triethyl amine, and 300 mL of chloroform. 22.0 Grams of the desired product was obtained, m.p. 167-169° C (dec.). Mass spectrum (EI, M⁺) *m/z* 257/259. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.93 (s, 1H), 7.80 (t, 1H), 7.73 (s, 1H), 7.52 (s, 1H), 7.25 (m, 2H), 7.16 (s, 1H), 4.07 (d, 2H), and 2.27 ppm (s, 3H).

15 A mixture of 2-[3-(3-chloro-4-methylphenyl)-thioureido]-acetamide (10.0 g), ethyl iodide (17.5 g), and ethanol (200 mL) was heated at reflux for 2.5 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (500 mL) and water (500 mL). The organic phase was washed with water (2x300 mL). The organic phase was extracted with 2N HCl (2x500 mL). The acid extract was neutralized with solid sodium bicarbonate and extracted with ethyl acetate. The organic phase was washed with water, dried over anhydrous Na₂SO₄ then evaporated to dryness. The residue was stirred in diethyl ether and filtered to give the title compound (8.4 g) as a white solid, m.p. 133-135° C. Anal. Calcd. for. C₁₂ H₁₃ Cl N₂ O S: C, 53.63; H, 4.88; N, 10.42. Found: C, 53.66; H, 4.78; N, 10.39. Mass spectrum (EI, M⁺) *m/z* 268/270. ¹H-NMR (DMSO-d₆; 400 MHz) δ 7.47 (d, 1H), 7.43 (d, 1H), 7.20 (dd, 1H), 4.29 (s, 2H), 3.07 (q, 2H), 2.36 (s, 3H), and 1.28 ppm (t, 3H).

EXAMPLE 13

3-(4-Chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

30

2-[3-(4-Chloro-2-methylphenyl)-thioureido]-acetamide was prepared by the procedure described in Example 11 using 18.36 g of 4-chloro-2-methylphenyl-isothiocyanate, 11.05 g of glyciamide hydrochloride, 10.1 g of triethyl amine, and 300 mL of chloroform. 21.4 Grams of the desired compound was obtained, m.p. 170-

-20-

172° C (dec.). Mass spectrum (EI, M⁺) *m/z* 257/259. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.38 (s, 1H), 7.62 (broad s, 1H), 7.45 (s, 1H), 7.35 (d, 1H), 7.32 (d, 1H), 7.21 (m, 1H), 7.12 (s, 1H), 4.06 (d, 2H), and 2.17 ppm (s, 3H).

5 The title compound was prepared by the procedure described in Example 6 using 18.0 g of 2-[3-(4-chloro-2-methylphenyl)-thioureido]-acetamide, and 25.0 g of ethyl iodide. The hydrochloride salt was prepared in ethereal hydrogen chloride. Crystallization from ethyl acetate afforded the title compound as an off-white solid, mono-hydrochloride (17.6 g), m.p. 166-168° C (dec.). Anal. Calcd. for. C₁₂ H₁₃ Cl₁₀ N₂ O S . HCl: C, 47.22; H, 4.62; N, 9.18. Found: C, 47.24; H, 4.45; N, 9.05. Mass spectrum (+FAB, [M+H]⁺) *m/z* 269/271. ¹H-NMR (DMSO-d₆; 400 MHz) δ 9.05-9.78 (broad s, 2H), 7.53 (m, 1H), 7.44 (d, 1H), 7.41 (d, 1H), 7.33 (d, 1H), 4.48 (q, 2H), 3.20 (m, 2H), 2.13 (s, 3H), and 1.29 ppm (t, 3H).

15

EXAMPLE 14

3-(2,6-Dimethylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one

20 A mixture of 2,6-dimethylphenyl-isothiocyanate (16.3 g), glyciamide hydrochloride (11.05 g), triethyl amine (12.0 g), and chloroform (250 mL) was heated at reflux for 3 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (500 mL) and washed with 1N HCl (300 mL) then with water (300 mL). The organic phase was evaporated to dryness, then the residue was stirred with diethyl ether. The solid was collected by filtration and dried to afford 2-[3-(2,6-25 dimethylphenyl)-thioureido]-acetamide as a solid (18.3 g). Mass spectrum (EI, M⁺) *m/z* 237. This compound was used without further purification in the preparation of the title compound.


30 The title compound was prepared by the procedure described in Example 12 using 8.0 g of 2-[3-(2,6-dimethylphenyl)-thioureido]-acetamide, 25.0 g of ethyl iodide, and (200 mL) ethanol. Crystallization from hexane/diethyl ether mixture afforded the title compound as a light yellow solid (2.4 g), m.p. 86-88° C. Anal. Calcd. for. C₁₂ H₁₆ N₂ O S: C, 62.87; H, 6.49; N, 11.28. Found: C, 62.98; H, 6.57; N, 11.30. Mass spectrum (EI, M⁺) *m/z* 248. ¹H-NMR (DMSO-d₆; 400 MHz)

-21-

δ 7.27-7.30 (m, 1H), 7.21 (m, 1H), 7.19 (m, 1H), 7.33 (d, 1H), 4.42 (s, 2H), 3.06 (q, 2H), 2.07 (s, 6H), and 1.26 ppm (t, 3H).

What is claimed is:

(1) A compound of formula I:




wherein

R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl of 1 to 6 carbon atoms, perfluoroalkyl of 1 to 6 carbon atoms, 10 alkoxy of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms, hydroxy, alkanoyloxy of 2 to 6 carbon atoms, aroyloxy of 7 to 11 carbon atoms or arylalkanoyloxy of 8 to 16 carbon atoms;

R³ is alkyl of 1 to 6 carbon atoms, aryl of 6 to 10 carbon atoms or arylalkyl of 7 to 12 carbon atoms;

15 or a pharmaceutically acceptable salt thereof.

(2) A compound of formula I:



20

wherein

R is phenyl or phenyl optionally substituted with one or more groups selected from halogen, alkyl of 1 to 3 carbon atoms, perfluoromethyl, alkoxy of 1 to 3 carbon atoms, perfluoromethoxy, hydroxy or alkanoyloxy of 2 to 4 carbon atoms;

25 R³ is alkyl of 1 to 3 carbon atoms or arylalkyl or 7 to 9 carbon atoms; or a pharmaceutically acceptable salt thereof.

(3) The compound of Claim 1 which is 2-ethylsulfanyl-3-(4-fluorophenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

-23-

(4) The compound of Claim 1 which is 3-(5-chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

5 (5) The compound of Claim 1 which is 3-(5-chloro-2-methoxyphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(6) The compound of Claim 1 which is 3-(2,6-dichlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

10 (7) The compound of Claim 1 which is 2-benzylsulfanyl-3-(5-chloro-2-methylphenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

15 (8) The compound of Claim 1 which is 3-(2-chlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(9) The compound of Claim 1 which is 2-ethylsulfanyl-3-(2-tolyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

20 (10) The compound of Claim 1 which is 3-(2-chloro-6-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(11) The compound of Claim 1 which is 2-ethylsulfanyl-3-phenyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

25 (12) The compound of Claim 1 which is 3-(2,6-dimethylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

30 (13) A compound of Claim 1 which is 2-ethylsulfanyl-3-(5-fluoro-2-methylphenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(14) A compound of Claim 1 which is 3-(3-chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

-24-


(15) A compound of Claim 1 which is 3-(3-chloro-4-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(16) A compound of Claim 1 which is 3-(4-chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof.

(17) A process for preparing a compound of formula I or a pharmaceutical by acceptable salt thereof which comprises:

a) reacting a 2-thioxo-imidazolidin-4-one of formula (A):


10



wherein R is as defined in Claim 1 with methyl iodide to give a corresponding compound of formula I wherein R³ is methyl, or

15

b) reacting a thiourea amide of formula 3:



20

wherein R is as defined in Claim 1 with a compound of formula:



(18) A compound of formula I as defined in any one of Claims 1 to 16 or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

25

-25-

(19) Use of a compound of formula I as defined in **Claim 1** or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for increasing blood serum HDL cholesterol levels in a mammal.

5 (20) Use of the compound 3-(5-chloro-2-methylphenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for increasing blood serum HDL cholesterol levels in a mammal.

10 (21) Use of the compound 3-(2,6-dichlorophenyl)-2-ethylsulfanyl-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for increasing blood serum HDL cholesterol levels in a mammal.

15 (22) Use of the compound 2-benzylsulfanyl-3-(5-chloro-2-methylphenyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for increasing blood serum HDL cholesterol levels in a mammal.

20 (23) Use of the compound 2-ethylsulfanyl-3-(2-tolyl)-3,5-dihydro-imidazol-4-one or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for increasing blood serum HDL cholesterol levels in a mammal.

25 (24) A method for increasing blood serum HDL cholesterol level in a mammal which comprises administering to said mammal an effective amount of a compound as claimed in any one of **Claims 1 to 16**.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/19108

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D233/86 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HETEROCYCLES (HTCYAM,03855414);95; VOL.40 (2); PP.851-66, TECHNICAL UNIV. VIENNA; INST. ORG. CHEM.; VIENNA; A-1060; AUSTRIA (AT), XP000651161</p> <p>SAUTER F ET AL: "[Bis(methylthio)methylene]amino esters (BMMA): novel reagents for annelation of pyrimidine moieties" see page 853, scheme 3</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/-</p>	1,2,17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

2

Date of the actual completion of the international search

12 March 1997

Date of mailing of the international search report

18.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Steedijk, M

INTERNATIONAL SEARCH REPORT

Int.	nat Application No PCT/US 96/19108
------	---------------------------------------

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 49, no. 17, 10 September 1955 Columbus, Ohio, US; JEFFREYS: "The cyclization of substituted ..." page 11658; XP002027350 &J.Chem.Soc. 1954,2221-2230 see abstract ---	1,2,17
A	EP 0 578 516 A (ROUSSEL UCLAF) 12 January 1994 cited in the application see page 3, formula I ---	1-25
A	WO 94 20460 A (SMITHKLINE BEECHAM CORP ;WEINSTOCK JOSEPH (US)) 15 September 1994 cited in the application see page 7, formula (33) ---	1-25
A	J. MED. CHEM., vol. 35, 1992, pages 4384-4392, XP002027356 HARRIS ET AL.: "Acyl-CoA:cholesterol ..." see the whole document ----	1-25
P,X	US 5 554 607 A (ELOKDAH HASSAN M ET AL) 10 September 1996 see the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/19108

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0578516 A	12-01-94	FR 2694290 A CA 2097247 A JP 7291939 A US 5434176 A US 5589497 A US 5556983 A	04-02-94 09-01-94 07-11-95 18-07-95 31-12-96 17-09-96
WO 9420460 A	15-09-94	NONE	
US 5554607 A	10-09-96	NONE	